Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu.
1995 · Journal of Clinical Oncology · 183 citations
https://doi.org/10.1200/jco.1995.13.9.2281
L
Lionel D. Lewis
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
258
Papers
5.8K
Citations
43
h-index
103
i10-index
Lionel D. Lewis is an academic researcher from American Society of Clinical Oncology. The author has contributed to research in topics: Cancer Treatment and Pharmacology & Pharmacogenetics and Drug Metabolism & Cancer Immunotherapy and Biomarkers. The author has an h-index of 43, co-authored 220 publications.
ORCID: 0000-0003-1164-5157Papers by this author
worksTumor Cell Targeting by Iron Oxide Nanoparticles Is Dominated by Different Factors In Vitro versus In Vivo
2015 · PLoS ONE · 51 citations
https://doi.org/10.1371/journal.pone.0115636
Clinical Trials of Bispecific Antibody MDX-210 in Women with Advanced Breast or Ovarian Cancer that Overexpresses HER-2/neu
1995 · Journal of Hematotherapy · 48 citations
https://doi.org/10.1089/scd.1.1995.4.471
A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors
2013 · BMC Cancer · 42 citations
https://doi.org/10.1186/1471-2407-13-20
Phase I Pilot Trial of the Bispecific Antibody MDXH210 (anti-FcγRI X anti–HER-2/neu) in Patients Whose Prostate Cancer Overexpresses HER-2/neu
2001 · Journal of Immunotherapy · 35 citations
https://doi.org/10.1097/00002371-200101000-00009
The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia
2012 · Pharmacogenetics and Genomics · 27 citations
https://doi.org/10.1097/fpc.0b013e32835b16d8
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat